B+
Bull case
0%
Probability
Target price
$31.00
+31.2% vs current
ELAN
Elanco Animal HealthCNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
0%
Probability
Target price
$27.00
+14.3% vs current
B-
Bear case
0%
Probability
Target price
$21.00
-11.1% vs current
AI sentiment snapshot
Latest data as of 2026-05-08
Recent news sentiment (30D)
+0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+62.0
Score
AI commentary
Post-earnings tone is positive but still better described as constructive monitoring than broad capitulation by bears. Primary company materials clearly support a beat-and-raise interpretation, and checked secondary coverage showed favorable initial headlines plus some target increases after the print. However, analyst-revision breadth is still incomplete in this packet, the peer set is loose, and the deterministic model prior remains slightly negative beyond 5 days, so confidence should stay moderate rather than aggressive.
RankAlpha Sentiment Codex - 2026-05-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-06eventQ1 beat-and-raise resets the near-term narrativeMedium impact
Elanco's May 6, 2026 earnings release reported Q1 revenue of $1.371B (+15% reported, +10% organic constant currency), adjusted EBITDA of $334M, adjusted EPS of $0.40, and raised full-year 2026 revenue, EBITDA, EPS, innovation, and year-end leverage targets; this is the clearest post-earnings positive catalyst in the packet and carries primary-source confirmation. [#8-K-2026-05-06]
2026-06-30catalystBefrena U.S. launch and continued Zenrelia/Credelio Quattro uptake are the main organic growth hooksHigh impact
The 10-Q says Befrena is anticipated to launch in Q2 2026, while Zenrelia and Credelio Quattro are already supporting pet-health growth and gaining international approvals; execution here matters because management tied the stronger 2026 outlook to innovation-led growth rather than one-off factors. [#10-Q-2026-05-06]
2027-12-31catalystAHV integration can deepen farm-animal growth but is more meaningful in 2027 than 2026Medium impact
The 10-Q says Elanco closed AHV International on April 30, 2026, expects only a modest 2026 revenue contribution, and sees a more meaningful impact beginning in 2027 as integration and commercial synergies develop; that supports a longer-duration upside case but not an immediate re-rate by itself. [#10-Q-2026-05-06]
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-08 • Updated nightlySource: Internal modelMethodology